Edwin Yau, MD
Medical Oncology · Buffalo, NYNPI 1568759769
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $139 of the $159 with a category attached, or 87.2%. 3 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 44.7% of the total. Reporting peaked in 2024 at $91 and has fallen 76.7% since, to $21 in 2025. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.
Across 7 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$71
- Dexcom, Inc.$68
- E.r. Squibb & Sons, L.L.C.$20
Across 26 payments — averaging $13,030 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$321K
- AstraZeneca$18K
What the payments were for
- Food & beverage$13987%
- Education$2013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 3 | $71 |
| Dexcom, Inc. | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
How this compares
$159 in reported general payments places this provider in the 20th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 25 | $384,766 |
| Prochlorperazine Maleate | 46 | $954 |
| Dexamethasone | 44 | $753 |
| Gabapentin | 12 | $151 |
| Olanzapine | 11 | $47 |
| Folic Acid | 17 | $45 |
| Prednisone | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Buffalo
- Ehsan MalekBuffalo$826K
- Marco DavilaBuffalo$437K
- Saby GeorgeBuffalo$234K
- Nikhil KhushalaniBuffalo$193K
- Francisco Hernandez IlizaliturriBuffalo$158K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.